Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434505 | 0.87 | ALDH1A1 (0.64) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL6560031 | 0.85 | ALDH1A1 (0.62) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL30565426 | 0.84 | ALDH1A1 (0.75) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL7237331 | 0.84 | ALDH1A1 (0.75) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL298044 | 0.84 | TSHR (0.62) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL30632630 | 0.84 | TSHR (0.62) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL1905900 | 0.84 | ALDH1A1 (0.49) | ALDH1A1GAAGFERTSHRHPGD | |
| SCHEMBL7266886 | 0.84 | ALDH1A1 (0.49) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL334074 | 0.81 | GAA (0.61) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL14438957 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GAAGFERCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042870-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| EP-3854781-B1 | DP ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-20220204468-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-11319296-B2 | DP antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20220033371-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3854781-A1 | DP ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2021-07-28 | — | — | EP | disclosed |
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| CN-101316591-B | Quinoline compound and pharmaceutical application thereof | ARGENTA ORAL THERAPEUTICS LTD. (GB) | 2012-02-01 | — | — | CN | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| CN-101316591-A | Quinolines and their therapeutic use | ARGENTA DISCOVERY LTD (GB) | 2008-12-03 | — | — | CN | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| EP-1453803-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | Zentaris GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003051837-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | ZENTARIS GMBH (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033371-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | ALDH1A1 2320/4885GAA 3281/4885GFER 3262/4885 |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | ALDH1A1 4201/4885GAA 4744/4885GFER 1099/4885 |
| US-20220204468-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | ALDH1A1 2320/4885GAA 3281/4885GFER 3262/4885 |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | ALDH1A1 4522/4885GAA 4163/4885GFER 4100/4885 |
| US-11319296-B2 | DP antagonist | OPRL1, CNR1, NPSR1 | ALDH1A1 2320/4885GAA 3281/4885GFER 3262/4885 |
| US-20250042870-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | ALDH1A1 2320/4885GAA 3281/4885GFER 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.